护士健康研究中镇痛药使用与卵巢癌风险的关联
结果显示,当前使用低剂量阿司匹林(≤100 mg)与卵巢癌风险降低相关(HR 0.77,95%CI 0.61-0.96),而标准剂量阿司匹林无此关联;当前使用非阿司匹林NSAIDs与风险升高相关(HR 1.19,95%CI 1.00-1.41),且使用时长和累积周片数呈正趋势。对乙酰氨基酚未见明确关联。
要点
- 低剂量阿司匹林(≤100 mg)当前使用与卵巢癌风险降低相关(HR 0.77)。
- 标准剂量阿司匹林(325 mg)当前使用与卵巢癌风险无显著关联。
- 当前使用非阿司匹林NSAIDs与卵巢癌风险升高相关(HR 1.19),需进一步确认。
核心结论
- 低剂量阿司匹林常规使用与卵巢癌风险降低相关,与非阿司匹林NSAIDs长期高量使用与风险升高相关。
主要发现
- 当前使用任何剂量阿司匹林 vs 非使用与卵巢癌风险无显著关联(HR 0.99,95%CI 0.83-1.19)。
- 当前使用低剂量阿司匹林(≤100 mg) vs 非使用与卵巢癌风险降低相关(HR 0.77,95%CI 0.61-0.96)。
- 当前使用标准剂量阿司匹林(325 mg) vs 非使用与卵巢癌风险无显著关联(HR 1.17,95%CI 0.92-1.49)。
- 对乙酰氨基酚使用与卵巢癌风险未见明确关联。
关键数值与推荐
- 低剂量阿司匹林定义为≤100 mg,标准剂量阿司匹林为325 mg。
临床怎么用
- 对于卵巢癌风险咨询,可提及低剂量阿司匹林常规使用与风险降低的关联,但需权衡出血等风险。
- 长期高量使用非阿司匹林NSAIDs可能与卵巢癌风险升高相关,临床用药时应考虑此潜在关联。
局限性
- 研究人群以非西班牙裔白人为主(NHS 93%,NHSII 92%),结果外推需谨慎。
- 非阿司匹林NSAIDs与卵巢癌风险升高的关联需进一步确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Ovarian cancer is a highly fatal malignant neoplasm with few modifiable risk factors. Case-control studies have reported a modest reduced risk of ovarian cancer among women who frequently use aspirin or regularly use low-dose aspirin. OBJECTIVE: To evaluate whether regular aspirin or nonaspirin nonsteroidal anti-inflammatory drug (NSAID) use and patterns of use are associated with lower ovarian cancer risk. DESIGN, SETTING, AND PARTICIPANTS: This cohort study analyzed NSAID use and ovarian cancer diagnosis data from 2 prospective cohorts, 93 664 women in the Nurses' Health Study (NHS), who were followed up from 1980 to 2014, and 111 834 in the Nurses' Health Study II (NHSII), who were followed up from 1989 to 2015. Follow-up was completed on June 30, 2014, for the NHS and June 30, 2015, for NHSII. Data were analyzed from June 13, 2016, to September 18, 2017. EXPOSURES: For each analgesic type (aspirin, low-dose aspirin, nonaspirin NSAIDs, and acetaminophen), timing, duration, frequency, and number of tablets used were evaluated; exposure information was updated every 2 to 4 years. MAIN OUTCOMES AND MEASURES: Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% CIs for associations of aspirin, nonaspirin NSAIDs, and acetaminophen with risk of epithelial ovarian cancer. All statistical tests were 2-sided, with a significance level of .05. RESULTS: In the NHS, the mean (SD) age at baseline (1980) was 45.9 (7.2) years, and 93% of participants identified as non-Hispanic white. In the NHSII, the mean age at baseline (1989) was 34.2 (4.7) years, and 92% identified as non-Hispanic white. Among the 205 498 women in both cohorts, there were 1054 cases of incident epithelial ovarian cancer. Significant associations between aspirin and ovarian cancer risk were not observed when current vs nonuse of any aspirin was evaluated regardless of dose (HR, 0.99; 95% CI, 0.83-1.19). However, when low-dose (≤100-mg) and standard-dose (325-mg) aspirin were evaluated separately, an inverse association for low-dose aspirin (HR, 0.77; 95% CI, 0.61-0.96), but no association for standard-dose aspirin (HR, 1.17; 95% CI, 0.92-1.49) was observed. Current use of nonaspirin NSAIDs was positively associated with risk of ovarian cancer compared with nonuse (HR, 1.19; 95% CI, 1.00-1.41), and significant positive trends for duration of use (P = .02 for trend) and cumulative average tablets per week (P = .03 for trend) were observed. There were no clear associations for the use of acetaminophen. CONCLUSIONS AND RELEVANCE: These results appear to be consistent with case-control studies that show a reduced risk of ovarian cancer among regular users of low-dose aspirin. An increased risk of ovarian cancer with long-term high-quantity use of other analgesics, particularly nonaspirin NSAIDs, was observed, although this finding requires confirmation.
引用
- Barnard ME, Poole EM, Curhan GC, et al. Association of Analgesic Use With Risk of Ovarian Cancer in the Nurses' Health Studies. JAMA Oncol. 2018. PMID: 30286239. doi:10.1001/jamaoncol.2018.4149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。